Patient must provide written informed consent prior to participating in this protocol
Patient must have been prescribed TECELRA®
Patient's commercially manufactured product does not meet the commercial release specification
Repeat manufacture is not feasible or is not clinically appropriate per Investigator assessment in consultation with per consultation with USWM CT
Repeat leukapheresis is not feasible or is not clinically appropriate per Investigator assessment
The Investigator has confirmed a favorable benefit:risk profile, following sponsor evaluation of the NC afami-cel, and deems proceeding with treatment under this EAP is in the best interest of the patient
Patient deemed medically fit and stable to receive NC afami-cel per Investigator assessment
Female patients with reproductive potential must have a negative serum or urine pregnancy test within 7 days of initiating lymphodepleting chemotherapy
You may not be if
Patient has contraindication(s) as per the TECELRA® USPI
Do not use TECELRA® in adults who are heterozygous or homozygous for HLA-A\*02:05P
Clareo Health | Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
